Skip to content
DraconiticResearch
Search Sources API
186,086 studies31 sourcesUpdated 19 min ago
Peer-reviewedCC BY-NCBleeding, Thrombosis and Vascular Biology

CO051 | PROTEIN S HEERLEN AND OTHER PROS1 GENE VARIANTS IN PROTEIN S-DEFICIENT PATIENTS: A SINGLE-CENTER STUDY

Abstract

Background and Aims. Diagnosing protein S (PS) deficiency is challenging due to varied functional defects and diagnostic assays, highlighting the importance of genetic characterization of the PROS1 gene. The clinical significance of the Heerlen (Ser501Pro) variant remains unclear. This study aimed to determine the frequency of coding-region variants in individuals with PS deficiency and assess their correlation with PS phenotype and thrombotic risk. Methods. We analyzed 55 subjects with persistently reduced free PS levels (<65%) and no identifiable causes of acquired deficiency. Free PS was measured using immunological methods. Genetic analysis of peripheral blood DNA was conducted with next-generation sequencing to detect germline PROS1 variants. Variants were annotated, classified by established criteria, and correlated with biochemical and clinical data. Results. The cohort comprised 34 females (61.8%) and 21 males (38.2%), with a mean free PS level of 41.6% (range 7–65%). Thrombotic events occurred in 38.2% of subjects (venous n=17; arterial n=4). The median age at the first event was 49 years (range 17–88), with recurrence in 9.1%. Family history revealed both PS deficiency and venous thromboembolism (VTE) in 21.8% of patients, VTE alone in 18.1%, and asymptomatic PS deficiency in 21.8%. Free PS levels did not differ significantly between patients with and without VTE (41.1% vs 42.4%, p = 0.7469). No mutations were found in 27 patients (49.1%, group A), of whom 40.7% had VTE and 29.6% had a family history of VTE. Thirteen patients (23.6%, group B) carried the Heerlen variant; 7.6% had VTE and 30.7% had a family history of VTE. Fifteen patients (27.3%, group C) carried other PROS1 variants; 33.3% had VTE and 60% had a family history of VTE. Detected variants included Arg330Trp (n=3, two families), Gly357Arg (n=2, unrelated), and single cases (3.6% each) of Ala525Val, Pro667Leu, Glu360Lys, Ala557Val, Ile591Met, Arg316His, Glu437Lys, Tyr332Ter, Gln563Ter, and Ile546MetfsTer16. Median free PS levels were 48% in group A (range 7-64%) and B (range 25-65%) and 35% (range in group C (10-53%)) (group C vs A or B, p < 0.001) (Figure). Patients with truncating variants (frameshift and nonsense mutations) (n=3) had lower free PS levels (median 12%, range 10–16), indicating a severe loss-of-function effect. Conclusions. PS-deficient subjects without coding-sequence variants or with the Heerlen variant had significantly higher free PS levels than carriers of other PROS1 variants. Additionally, carriers of the Heerlen variant had a low rate of VTE. Amino acid substitutions were identified in only about half of patients with free PS deficiency, suggesting that other defects may involve non-coding mutations or copy number variations affecting PROS1 expression.

Related

  1. Potential for pathogenic protein acylation in succinate dehydrogenase-deficient pheochromocytoma and paraganglioma.
    Sherry X Zhou, L James Maher
    Endocrine-related cancerPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC
  2. Functional analysis of NANOS protein variants identified in men with infertility employing zebrafish embryos
    S. Madiwale, A. Gupta, L. Schmidthuis +6
    medRxivPreprintAll rights reservedFull textObstetrics, gynaecology & paediatricsmedRxiv
  3. Incompletely penetrant protein-truncating variants confer developmental disorder risk through partial reductions in gene expression
    J. E. Hampstead, E. Delage, G. Khazeeva +13
    medRxivPreprintPublic domainFull textHuman geneticsmedRxiv
  4. Novel Genetic Variants of the CHD2 Gene in cis Position in a Patient with Epileptic Encephalopathy: A Case Report and In Silico Analysis of the Impact of the Variants on the Protein
    Andrew S. Zuev, Elizaveta A. Fonova, Daria S. Kuznetsova +2
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Full textPsychiatry & mental healthCrossrefEurope PMC
  5. Novel LRRK2 Kinase Inhibitors Enhance Phosphorylation and Restore Adapter Protein Binding in LRRK2 Variants
    A. W. Garofalo, M. D. Schonemann, M. Santoro +2
    bioRxivPreprintCC BY-NC-NDFull textNeurologybioRxiv
BibTeX
@article{ramundo2026co051,
  title = {{CO051 | PROTEIN S HEERLEN AND OTHER PROS1 GENE VARIANTS IN PROTEIN S-DEFICIENT PATIENTS: A SINGLE-CENTER STUDY}},
  author = {Francesco Ramundo},
  journal = {Bleeding, Thrombosis and Vascular Biology},
  year = {2026},
  month = oct,
  url = {https://www.btvb.org/btvb/article/view/753},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - CO051 | PROTEIN S HEERLEN AND OTHER PROS1 GENE VARIANTS IN PROTEIN S-DEFICIENT PATIENTS: A SINGLE-CENTER STUDY
AU  - Francesco Ramundo
PY  - 2026
DA  - 2026/10/26
JO  - Bleeding, Thrombosis and Vascular Biology
UR  - https://www.btvb.org/btvb/article/view/753
AB  - Background and Aims. Diagnosing protein S (PS) deficiency is challenging due to varied functional defects and diagnostic assays, highlighting the importance of genetic characterization of the PROS1 gene. The clinical significance of the Heerlen (Ser501Pro) variant remains unclear. This study aimed to determine the frequency of coding-region variants in individuals with PS deficiency and assess their correlation with PS phenotype and thrombotic risk. Methods. We analyzed 55 subjects with persistently reduced free PS levels (<65%) and no identifiable causes of acquired deficiency. Free PS was measured using immunological methods. Genetic analysis of peripheral blood DNA was conducted with next-generation sequencing to detect germline PROS1 variants. Variants were annotated, classified by established criteria, and correlated with biochemical and clinical data. Results. The cohort comprised 34 females (61.8%) and 21 males (38.2%), with a mean free PS level of 41.6% (range 7–65%). Thrombotic events occurred in 38.2% of subjects (venous n=17; arterial n=4). The median age at the first event was 49 years (range 17–88), with recurrence in 9.1%. Family history revealed both PS deficiency and venous thromboembolism (VTE) in 21.8% of patients, VTE alone in 18.1%, and asymptomatic PS deficiency in 21.8%. Free PS levels did not differ significantly between patients with and without VTE (41.1% vs 42.4%, p = 0.7469). No mutations were found in 27 patients (49.1%, group A), of whom 40.7% had VTE and 29.6% had a family history of VTE. Thirteen patients (23.6%, group B) carried the Heerlen variant; 7.6% had VTE and 30.7% had a family history of VTE. Fifteen patients (27.3%, group C) carried other PROS1 variants; 33.3% had VTE and 60% had a family history of VTE. Detected variants included Arg330Trp (n=3, two families), Gly357Arg (n=2, unrelated), and single cases (3.6% each) of Ala525Val, Pro667Leu, Glu360Lys, Ala557Val, Ile591Met, Arg316His, Glu437Lys, Tyr332Ter, Gln563Ter, and Ile546MetfsTer16. Median free PS levels were 48% in group A (range 7-64%) and B (range 25-65%) and 35% (range in group C (10-53%)) (group C vs A or B, p < 0.001) (Figure). Patients with truncating variants (frameshift and nonsense mutations) (n=3) had lower free PS levels (median 12%, range 10–16), indicating a severe loss-of-function effect. Conclusions. PS-deficient subjects without coding-sequence variants or with the Heerlen variant had significantly higher free PS levels than carriers of other PROS1 variants. Additionally, carriers of the Heerlen variant had a low rate of VTE. Amino acid substitutions were identified in only about half of patients with free PS deficiency, suggesting that other defects may involve non-coding mutations or copy number variations affecting PROS1 expression.
SN  - 2785-5309
ER  -